Context drops bispecific T-cell engager on cost-cutting initiative
Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
MSD (Merck & Co) and Gilead Sciences have terminated a Phase III trial evaluating a duo of blockbuster oncology medicines…
-
MSD posts a victory and defeat for anti-TL1A in skin condition and rare lung disease
MSD (Merck & Co) has secured a win for its anti-TL1A hopeful, tulisokibart, in painful skin condition, hidradenitis suppurativa (HS),…
-
Rocket points to Danon gene therapy’s safety after Phase II protocol change
Rocket Pharmaceuticals has safely treated three patients with its one-time Danon disease gene therapy, RP-A501, during a Phase II study…
-
Moderna adds new cohort to Phase III vaccine trial after interim data miss
Moderna is looking to add an additional cohort to a late-stage study evaluating its norovirus vaccine hopeful, mRNA-1403, after the…
-
GSK’s ADC prospects brighten further with Hansoh’s second Phase III triumph
GSK’s bet on Hansoh Pharma is continuing to bear fruit for its oncology portfolio, as the Chinese biotech posted another…
-
CSL eyes Andembry spot on paediatric HAE market amid positive Phase III results
Australian biotech CSL is heading to regulators after the company’s marketed hereditary angioedema (HAE) therapy, Andembry (garadacimab), demonstrated its promise…
-
J&J’s multiple myeloma combo cuts risk of death by 62% in Phase III study
Johnson & Johnson (J&J) has posted a duo of Phase III wins for two of its budding multiple myeloma combination…
-
Crystalys banks $130m to progress gout drug, plan for commercial readiness
Crystalys Therapeutics has secured $130m in a Series B raise to push its gout therapy, dotinurad, further down the pipeline,…
-
Gilead, MSD chart weekly HIV med’s course to approval on SoC non-inferiority
Gilead and MSD (Merck & Co) have released data for their two-drug combination human immunodeficiency virus (HIV) therapy, islatravir-lenacapavir (ISL/LEN),…